Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
Study Information
Alliance Study ID: NCCTG-N0342
NCT Study ID (ClinicalTrials.gov): NCT00100945
Disease or Cancer Type: Gastrointestinal Cancers – Pancreatic / Gastric / Esophageal / Liver / Biliary
Alliance Study Chair: Aminah Jatoi, MD
Status: COMPLETED
Study Description
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with locally advanced esophageal cancer.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information